Work

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-127481

Authors: Sanjal Desai, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Mark A. Ahlman, Andrea Nicole Lucas, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Wyndham Wilson

Institutions: MedStar Washington Hospital Center, National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institutes of Health Clinical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2986874418

Cites:

Cited by:

Related to: 10